Develops medicines for autoimmune diseases. Focuses on therapies for amyotrophic lateral sclerosis (ALS). Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
There is $133.3M in the vault; even if every debt were paid off, $132.7M would remain.
Over the last 12 months, company executives reported 28 buys and 8 sells. Management buying with its own money is usually read as a good sign.
A loss of $45.6M against $0 in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 19/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 29/100.
On our five-subject report card, ELDN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ELDN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (19/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.